Physician profile
Rachel Eicher
NPI 1164906996
$2,751.13
in general payments reported to CMS, 2019-2025
22 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $777 · 2023: $605 · 2024: $702 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $556.62 | 2021-2025 | General - Pain Management, General - Therapies, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $303.59 | 2021-2025 | Proclaim, Eterna |
| International Rehabilitative Sciences, INC | $303.54 | 2022 | |
| Nevro Corp. | $279.29 | 2021-2024 | Senza |
| Ibsa Pharma INC. | $195.82 | 2021-2024 | Tirosint, Licart, Licart |
| Azurity Pharmaceuticals, INC. | $136.49 | 2023-2025 | Horizant, Horizant |
| Medtronic, INC. | $136.49 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Scilex Pharmaceuticals INC. | $134.91 | 2023-2024 | Ztlido |
| Forte Bio-Pharma LLC | $116.36 | 2024 | Prolate, Nalocet |
| Relievant Medsystems, INC. | $106.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $101.80 | 2022-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $71.08 | 2023-2024 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.12 | 2025 | Relistor |
| Vertex Pharmaceuticals Incorporated | $55.15 | 2025 | |
| Curonix LLC | $36.74 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $35.18 | 2023-2025 | Durolane, Durolane |
| Averitas Pharma INC. | $26.75 | 2025 | Qutenza |
| Biotronik Nro, INC. | $24.74 | 2025 | Prospera |
| Arbor Pharmaceuticals, INC. | $24.58 | 2021 | |
| Stimwave Technologies Incorporated | $15.98 | 2021 | |
| Avanos Medical | $13.28 | 2021 | |
| Hikma Pharmaceuticals USA | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Eicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.